{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:05:53Z","timestamp":1790395553912,"version":"4.1.0"},"reference-count":49,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,11,2]]},"DOI":"10.1080\/13543776.2022.2143264","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T13:56:12Z","timestamp":1668002172000},"page":"1161-1173","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":34,"title":["Small molecule modulators of IL-17A\/IL-17RA: a patent review (2013-2021)"],"prefix":"10.1080","volume":"32","author":[{"given":"Bidong","family":"Zhang","sequence":"first","affiliation":[{"name":"University of Groningen","place":["Groningen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"D\u00f6mling","sequence":"additional","affiliation":[{"name":"University of Groningen","place":["Groningen, The Netherlands"]},{"name":"Palack\u00fd University Olomouc","place":["Olomouc, Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2586"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0514-y"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2013.58"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.021"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20090"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.03.027"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12142"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1473552"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02446-6"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.566922"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1039\/C7MD00464H"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2880"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01693"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep30859"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep26071"},{"key":"e_1_3_5_19_1","unstructured":"Ensemble Therapeutics Corporation. Macrocyclic compounds for modulating IL-17. WO2013116682A1. 2013."},{"key":"e_1_3_5_20_1","unstructured":"Ensemble Therapeutics Corporation. Macrocyclic compounds for modulating IL-17. US20150005319A1. 2015."},{"key":"e_1_3_5_21_1","unstructured":"Ensemble Therapeutics Corporation. Compounds for modulating IL-17. WO2014066726A2. 2014."},{"key":"e_1_3_5_22_1","unstructured":"Ucb Biopharma Sprl. Spirocyclic indolines as IL-17 modulators. WO2018229079A1. 2018."},{"key":"e_1_3_5_23_1","unstructured":"Ucb Biopharma Sprl. Fused imidazole derivatives as IL-17 modulators. WO2019138017A1. 2019."},{"key":"e_1_3_5_24_1","unstructured":"Ucb Biopharma Sprl. Spirocyclic indane analogues as IL-17 modulators. WO2020011731A1. 2020."},{"key":"e_1_3_5_25_1","unstructured":"Ucb Biopharma Sprl. Benzimidazolone derivatives and analogues thereof as IL-17 modulators. WO2020120140A1. 2020."},{"key":"e_1_3_5_26_1","unstructured":"Ucb Biopharma Sprl. Benzimidazolone derivatives and analogues thereof as IL-17 modulators. WO2020120141A1. 2020."},{"key":"e_1_3_5_27_1","unstructured":"Ucb Biopharma Sprl. Fused imidazole derivatives as IL-17 modulators. WO2020260425A1. 2020."},{"key":"e_1_3_5_28_1","unstructured":"Ucb Biopharma Sprl. Fused imidazole derivatives as IL-17 modulators. WO2020260426A1. 2020."},{"key":"e_1_3_5_29_1","unstructured":"Ucb Biopharma Sprl. Imidazopyridine derivatives as IL-17 modulators. WO2020261141A1. 2020."},{"key":"e_1_3_5_30_1","unstructured":"Ucb Biopharma Sprl. Difluorocyclohexyl derivatives as IL-17 modulators. WO2021170627A1. 2021."},{"key":"e_1_3_5_31_1","unstructured":"Ucb Biopharma Sprl. Difluorocyclohexyl derivatives as IL-17 modulators. WO2021170631A1. 2021."},{"key":"e_1_3_5_32_1","unstructured":"Ucb Biopharma Sprl. Difluorocyclohexyl derivatives as IL-17 modulators. WO2021204800A1. 2021."},{"key":"e_1_3_5_33_1","unstructured":"Ucb Biopharma Sprl. Difluorocyclohexyl derivatives as IL-17 modulators. WO2021204801A1. 2021."},{"key":"e_1_3_5_34_1","unstructured":"Hitgen Inc. Preparation of immunomodulator for treating IL-17A mediated diseases. WO2019223718A1. 2019."},{"key":"e_1_3_5_35_1","unstructured":"Hitgen Inc. Enantioselective prepn. of ((methyl)pyrazolecarboxamido)methyl benzimidazoles as IL-17 immunomodulators. CN112341435A. 2021."},{"key":"e_1_3_5_36_1","unstructured":"Hitgen Inc. Preparation of (benzimidazolyl)(cyclobutylmethyl)acetamides as IL-17 immunomodulators. CN112341439A. 2021."},{"key":"e_1_3_5_37_1","unstructured":"Hitgen Inc. Preparation of imidazole derivatives as immunomodulators and used for treating IL-17A-mediated diseases. CN112341440A. 2021."},{"key":"e_1_3_5_38_1","unstructured":"Hitgen Inc. Enantioselective preparation of ((methyl)pyrazolecarboxamido)methyl benzimidazoles as IL-17 immunomodulators. CN112341441A."},{"key":"e_1_3_5_39_1","unstructured":"Hitgen Inc. Enantioselective preparation of (benzimidazolyl)oxypyrrolidine carboxylates as IL-17 immunomodulators. CN112341442A. 2021."},{"key":"e_1_3_5_40_1","unstructured":"Hitgen Inc. Preparation of benzimidazole derivatives as immune regulators. CN112341446A. 2021."},{"key":"e_1_3_5_41_1","unstructured":"Hitgen Inc. Preparation of benzimidazole derivatives as immune regulators. CN112341450A. 2021."},{"key":"e_1_3_5_42_1","unstructured":"Hitgen Inc. Compound as IL-17A inhibitor and use in the preparation of drugs for treating IL-17A-mediated diseases thereof. CN112341451A. 2021."},{"key":"e_1_3_5_43_1","unstructured":"Hitgen Inc. Immunomodulator and application thereof in treating IL-17A mediated disease. CN112341519A. 2021."},{"key":"e_1_3_5_44_1","unstructured":"Dice Alpha Inc. IL-17 Ligands And Uses Thereof. US2020247785A1. 2020."},{"key":"e_1_3_5_45_1","unstructured":"Dice Alpha Inc. IL-17A modulators and uses thereof. WO2021055376A1. 2021."},{"key":"e_1_3_5_46_1","unstructured":"Eli Lilly And Company. Imidazo[1 2-b]pyridazine IL-17A inhibitors. WO2020146194A1. 2020."},{"key":"e_1_3_5_47_1","unstructured":"Leo Pharma A\/S. Amino-acid anilides as small molecule modulators of IL-17. WO2020127685A1. 2020."},{"key":"e_1_3_5_48_1","unstructured":"Leo Pharma A\/S. Amino-acid anilides as small molecule modulators of IL-17. WO2020182666A1. 2020."},{"key":"e_1_3_5_49_1","unstructured":"Leo Pharma A\/S. Small molecule modulators of IL-17. WO2021250194A1. 2021."},{"key":"e_1_3_5_50_1","unstructured":"Leo Pharma A\/S. Small molecule modulators of IL-17. WO2021255086A1. 2021."},{"key":"e_1_3_5_51_1","unstructured":"Leo Pharma A\/S. Small molecule modulators of IL-17. WO2021255174A1. 2021."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2022.2143264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:53:05Z","timestamp":1769723585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2022.2143264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,2]]}},"alternative-id":["10.1080\/13543776.2022.2143264"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2022.2143264","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}